WSJ on FDA’s rejection of Moderna vax trial


[ Follow Ups ] [ Post Follow Up ] [ UCLA Open Forum ]

Posted by Dr.J on February 13, 2026 at 19:40:28

No doubt this will shock you, but BZ’s slimy sh!tbrained moron sh!tstain was lying again. Wall Street Journal:

It’s hard to recall a regulator who has done as much damage to medical innovation in as little time as Vinay Prasad. In his latest drive-by shooting, the leader of the Food and Drug Administration’s vaccine division rejected Moderna’s mRNA flu vaccine without even a cursory review. This is arbitrary government at its worst.

The FDA rarely refuses to review a drug or vaccine application. Our sources say the FDA has rejected only about 4% of applications without a review, typically when they are missing important information. That wasn’t the case with Moderna.

Dr. Prasad spiked Moderna’s flu vaccine because its Phase 3 trial was putatively not “adequate and well-controlled.” He quibbled that the control group in Moderna’s late-stage trial didn’t receive the “best-available standard of care.” He decides what is “best.”

Moderna launched a global randomized controlled trial in September 2024 with 41,000 participants, half of whom received its vaccine. The other half received a standard flu vaccine as a control. The FDA blessed its trial design, and agency staffers gave Moderna a thumbs up to apply for approval last August based on the results. Its vaccine was 27% more effective at preventing symptomatic cases of flu and 49% more effective against hospitalization than the standard flu vaccine.

Yet Dr. Prasad said Moderna should have used a high-dose flu vaccine as its control rather than a standard dose—though that wasn’t possible. In the U.S., high-dose flu vaccines are typically given only to seniors over age 65. They aren’t available in many European countries where Moderna conducted its trial. That’s in part because government-run health systems don’t want to pay for expensive high-dose vaccines. Irony alert: Dr. Prasad is a fan of single-payer healthcare.

Even so, Moderna’s vaccine proved equally effective as high-dose shots in a side-by-side comparison with a standard dose. One advantage of Moderna’s mRNA vaccines, however, is that they can be quickly adapted and manufactured to match new strains.

Trump and his equally malignant and incompetent minons hell bent on making diseases great again


Follow Ups:



Post a Followup

Name:
Email:
Password:

Subject:

Comments:

Optional Link URL:
Link Title:
Optional Image URL:


[ Follow Ups ] [ Post Follow Up ] [ UCLA Open Forum ]